{{citations missing|date=September 2009}}
{{Drugbox
| verifiedrevid = 470631324
| IUPAC_name = (1''S'',2''S'',3''R'',4''S'',5''S'')-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
| image = Voglibose structure.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|voglibose}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 83480-29-9
| ATC_prefix = A10
| ATC_suffix = BF03
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 476960
| PubChem = 444020
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04878
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 392046
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S77P977AG8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01665
<!--Chemical data-->
| C=10 | H=21 | N=1 | O=7
| molecular_weight = 267.28 g/mol
| smiles = OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FZNCGRZWXLXZSZ-CIQUZCHMSA-N
}}
'''Voglibose''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]], trade name '''Voglib''', marketed by Mascot Health Series) is an [[alpha-glucosidase inhibitor]] used for lowering post-prandial blood glucose levels in people with [[diabetes mellitus]]. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of [[Takeda Pharmaceutical Company]], Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in [[diabetes mellitus]].<ref>https://www.takeda.com/news/2008/20080526_3621.html</ref>

[[Postprandial]] [[hyperglycemia]] (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, [[acarbose]], [[miglitol]] and voglibose, of which voglibose is the newest. 

==References==
{{Reflist}}

{{Oral hypoglycemics and insulin analogs}}

[[Category:Alpha-glucosidase inhibitors]]
[[Category:Amino sugars]]